Results from the ABSORB IV Trial Reported at TCT 2017

DENVER – October 31, 2017 – Thirty-day results from ABSORB IV, the largest randomized everolimus-eluting bioresorbable vascular scaffold (BVS) trial to date, found BVS to be noninferior to a cobalt-chromium everolimus-eluting stent (CoCr-EES) for target lesion failure (TLF).

Findings were reported today at the 29th annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium. Sponsored by the Cardiovascular Research Foundation (CRF), TCT is the world’s premier educational meeting specializing in interventional cardiovascular medicine.

First generation BVS have been associated with higher rates of TLF and device thrombosis than current metallic drug-eluting stents. It has been thought that this may be in part due to suboptimal implantation technique used in early studies. Therefore, the ABSORB IV trial mandated the avoidance of smaller vessels, and aggressive pre-dilatation and routine high-pressure post-dilatation were emphasized.

ABSORB IV also permitted the enrollment of more complex and higher-risk patients than ABSORB III, with inclusion of troponin-positive acute coronary syndrome (ACS) and up to three lesions in a maximum of two epicardial coronary arteries, including thrombus. Patients were randomized 1:1 to BVS or CoCr-EES after successful pre-dilatation with a 1:1 sized balloon.

Between August 15, 2014 and March 31, 2017, 2,604 patients at 140 sites in five countries were randomized to BVS (N=1,296) versus CoCr-EES (N=1,308). Median age was 63 years; 28.0% of patients were female and 31.7% had diabetes. Among patients receiving BVS, pre-dilatation was performed in 99.8% of lesions, and post-dilatation was performed in 82.6% of lesions. The acute device success (delivery and deployment of the study scaffold/stent with residual stenosis <30%) was 94.6% for BVS compared to 99.0% for CoCr-EES (P<0.0001).

The primary endpoint of 30-day target lesion failure (TLF) was 5.0% for BVS versus 3.7% for CoCr-EES, a difference of 1.29% (Pnoninferiority=0.02; Psuperiority =0.11). As treated 30-day TLF was 4.6% for BVS versus 3.7% for CoCr-EES, a difference of 0.83% (Pnoninferiority=0.006). Patient-oriented major adverse cardiac events (PoCE) were 5.2% for BVS compared to 4.1% for CoCr-EES (P=0.17). However, the rate of 30-day ischemia-driven target vessel revascularization (ID-TVR) was 1.2% versus 0.2% (P=0.003), and the rate of device thrombosis was 0.6% in the BVS group and 0.2% in the CoCr-EES group (P=0.06).

“At 30 days, BVS was non-inferior to CoCr-EES for target lesion failure,” said Gregg W. Stone, MD, Professor of Medicine at Columbia University Medical Center, and Director of Cardiovascular Research and Education at the Center for Interventional Vascular Therapy at NewYork-Presbyterian Hospital. “The rates of non-peri-procedural MI and ID-TLR at 30 days were greater with BVS than with CoCr-EES, and a trend toward greater stent thrombosis with BVS was present. Compared to ABSORB III, reducing the number of very small vessels treated in ABSORB IV substantially reduced the device thrombosis rate in both groups. These results are largely consistent with those from earlier ABSORB trials, and highlight the need for continued advancements in device technology and standardized technique to further improve the early safety profile of BVS.”

The ABSORB IV trial was funded by Abbott Vascular. Dr. Stone reported that he is Chairman of the ABSORB global clinical trial program (uncompensated) and a consultant to Reva, Inc.

Press Contacts

Irma Damhuis
Director, External Relations
Tel: 646-434-4690

Judy Romero
Program Manager, External Relations
Tel: 646-434-4608

Eucomed Guidelines go into effect
1 January 2018, update your TCTMD profile to be eligible for Grant Support to attend CRF meetings including TCT! https://www.tctmd.com/